Crinetics Pharmaceuticals, Inc.
CRNXCrinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
Drugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Jun 30, 2026
15wMarket Overview
Stock performance and key metrics
3 upcoming, 3 past
Paltusotine
Acromegaly
Atumelnant
Congenital Adrenal Hyperplasia
atumelnant (CRN04894)
Congenital Adrenal Hyperplasia
Randomized: 40 mg Paltusotine
Carcinoid Syndrome
CRN09682
SST2-positive Neuroendocrine Neoplasms
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Paltusotine | Phase 3 | Acromegaly | - | - |
Atumelnant | Phase 3 | Congenital Adrenal Hyperplasia | - | - |
atumelnant (CRN04894) | Phase 2 | Congenital Adrenal Hyperplasia | - | - |
Randomized: 40 mg Paltusotine | Phase 2 | Carcinoid Syndrome | - | - |
CRN09682 | Phase 2 | SST2-positive Neuroendocrine Neoplasms | - | - |
Acromegaly
2 drugs in this indication
Congenital Adrenal Hyperplasia
2 drugs in this indication
Carcinoid Syndrome
1 drug in this indication
SST2-positive Neuroendocrine Neoplasms
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)